Clearstead Trust’s Pacira BioSciences PCRX Stock Holding History

Clearstead Trust’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20	Closed	-$516	–	1378
2025 Q3	$516	Hold	20	–	–	﹤0.01%	1371
2025 Q2	$478	Buy	+20	New	+$504	﹤0.01%	1341

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clearstead Trust's PCRX Position: Q4 2025 in Review

Clearstead Trust sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 20 shares — an estimated $516 sold.

Clearstead Trust first reported a position in PCRX in Q2 2025 and held it in 2 quarters. The position peaked at $516 in Q3 2025. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

Clearstead Trust reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
Clearstead Trust sold 20 Pacira BioSciences shares in Q4 2025, an estimated $516.
Clearstead Trust first reported a position in Pacira BioSciences in Q2 2025 and held it in 2 quarters.
Clearstead Trust's Pacira BioSciences position peaked at $516 in Q3 2025.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Clearstead Trust's 13F filing for Q4 2025, filed 9 Feb 2026.